HUTCHMED licenses KRAS-EGFR conjugate HMPL-A830 to GSK for $1.3bn
HUTCHMED has granted GSK an exclusive licence to develop and commercialise HMPL-A830, a dual-targeting cancer candidate, outside Mainland China, Hong Kong, Macau and Taiwan. The agreement includes a US$110 million upfront payment and potential milestone payments and royalties totalling up to US$1.295 billion, making it one of the larger oncology licensing transactions involving an Asia-headquartered biotech in recent years.
HMPL-A830 is classified by HUTCHMED as an Antibody-Targeted Therapy Conjugate, or ATTC. The construct links a selective KRAS small-molecule inhibitor payload to an anti-EGFR antibody, aiming to deliver the KRAS inhibitor directly to EGFR-expressing tumour cells while simultaneously blocking signalling through both receptors. HUTCHMED describes the approach as distinct from traditional antibody-drug conjugates, which typically pair antibodies with cytotoxins rather than targeted inhibitor payloads. Clinical development is expected to begin in the second half of 2026, with HUTCHMED retaining responsibility for the global Phase I programme under a ClinicalTrials.gov registration.
The deal
Initial development will focus on colorectal, pancreatic and lung cancer, three solid tumour types with notably high rates of KRAS mutation. KRAS alterations are found in approximately 44% of colorectal cancer cases, up to 89% of pancreatic ductal adenocarcinoma cases and around 34% of lung adenocarcinoma cases, according to a 2024 Nature Medicine review cited in the release. The GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Limited will take over all subsequent clinical development and commercialisation activity outside Greater China and will pay tiered royalties on annual net sales. HUTCHMED retains full rights in its home markets.
Under the agreement, GSK also holds a right of first negotiation on one earlier-stage ATTC candidate from HUTCHMED's pipeline, signalling potential appetite for a broader relationship. BofA Securities acted as HUTCHMED's exclusive financial adviser.
Johnny Cheng, acting chief executive and chief financial officer of HUTCHMED, said the collaboration "marks a significant step in maximising its potential as a treatment for patients, unlocking an entirely new class of precision oncology medicines."
Market context
The KRAS inhibitor space has attracted intense industry interest since Amgen's sotorasib and Mirati's adagrasib validated G12C-specific inhibition as a viable clinical strategy, yet durable responses have proved elusive and resistance driven by upstream EGFR reactivation is well documented, particularly in colorectal cancer. The ATTC format is positioned by HUTCHMED as a structural solution to that resistance mechanism, though the concept remains preclinical and the clinical hypothesis is unproven.
GSK has been building its oncology pipeline through a combination of internal research and external partnering. The HMPL-A830 deal fits a pattern seen across the industry, in which large pharma groups acquire pre-Phase I or Phase I assets from smaller biotechs at meaningful upfront values, accepting early-stage risk in exchange for first access to potentially differentiated mechanisms. Several competitors, including companies pursuing pan-RAS and non-G12C KRAS inhibition strategies, are also advancing next-generation programmes, meaning the field will be considerably more crowded by the time HMPL-A830 reaches pivotal-stage decisions.
For HUTCHMED, the deal provides near-term capital and global commercial infrastructure without relinquishing home-market rights, a structure that has become a preferred template for Chinese and Hong Kong-listed biotechs seeking international validation while preserving domestic optionality.